Paydirt
BH
Insider

Benjamin Hohl

CHIEF FINANCIAL OFFICER

Benjamin Hohl (CHIEF FINANCIAL OFFICER) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Enliven Therapeutics, Inc. (ELVN). The largest single filing was $296K of ELVN (10,000 sh × $29.58, as filed), executed Mar 6.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
returns measure stock purchases only
Filings, ttm
5
0 buys · 5 sells
Median delay
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.3M
shares × price, as filed
Last traded
Sep 17
Filed yesterday

Median ADV $83.7M across their filed names

Open performance
Volume by month
$544K$272K$0Oct 2024Apr 2025Oct 2025Apr 2026Oct 2024 · sells $544KDec 2024 · sells $105KMar 2026 · sells $296KJun 2026 · sells $149KJul 2026 · sells $275KAug 2026 · sells $270KSep 2026 · sells $288K
Buys $0 Sells $1.9M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 5 filings

Sector per market data · by filing · past 12 months

Most traded names
ELVN Enliven Therapeutics, Inc. ELVN · 0 buys · 9 sells 9 filings
Recent filings
ELVNSALE Enliven Therapeutics, Inc. View filing → $103K
4,250 sh × $24.27
Exec Sep 27 2024
Filed Oct 1 2024 · 5:30 PM ET